# Peptide Monitoring & Biomarker Protocols - Clinical Comparison Matrix

**For Healthcare Practitioners**  
**Last Updated:** November 29, 2025

---

## Overview

This matrix provides evidence-based monitoring protocols for peptide therapy, including baseline assessments, follow-up intervals, and biomarker interpretation guidelines.

---

## Universal Baseline Assessment (All Peptide Patients)

### Pre-Treatment Screening

| Assessment | Rationale | Frequency |
|------------|-----------|-----------|
| **Comprehensive Metabolic Panel** | Liver/kidney function, electrolytes | Baseline, then q12 weeks |
| **Complete Blood Count** | Immune status, anemia screening | Baseline, then q12 weeks |
| **Lipid Panel** | Cardiovascular risk, metabolic effects | Baseline, then q12 weeks |
| **HbA1c** | Glucose metabolism baseline | Baseline, then q12 weeks |
| **Thyroid Panel (TSH, Free T3/T4)** | Metabolic baseline, GH interaction | Baseline, then q24 weeks |
| **Medical History** | Contraindications, drug interactions | Baseline only |
| **Medication Review** | Interaction assessment | Baseline + ongoing |

### Risk Stratification

**Low Risk (Standard Monitoring):**
- Age <60 years
- No significant comorbidities
- Single peptide therapy
- Monitoring: Baseline + 12 weeks + 24 weeks

**Moderate Risk (Enhanced Monitoring):**
- Age 60-75 years
- 1-2 controlled comorbidities
- 2-3 peptide stack
- Monitoring: Baseline + 4 weeks + 12 weeks + 24 weeks

**High Risk (Intensive Monitoring):**
- Age >75 years
- Multiple comorbidities
- 4+ peptide stack or investigational peptides
- Monitoring: Baseline + 4 weeks + 8 weeks + 12 weeks + ongoing

---

## Peptide-Specific Monitoring Protocols

### Growth Hormone Secretagogues (CJC-1295, Ipamorelin, Sermorelin, GHRP-2/6)

| Biomarker | Baseline | Follow-Up | Target Range | Clinical Significance |
|-----------|----------|-----------|--------------|----------------------|
| **IGF-1** | Required | 4 weeks, then q12 weeks | Age-adjusted normal range (avoid >ULN) | Primary efficacy marker; cancer risk if excessive |
| **IGFBP-3** | Optional | q12 weeks if IGF-1 elevated | Normal range | Binding protein; context for IGF-1 |
| **Fasting Glucose** | Required | q12 weeks | <100 mg/dL | GH can impair insulin sensitivity |
| **HbA1c** | Required | q12 weeks | <5.7% | Monitor for glucose dysregulation |
| **Lipid Panel** | Required | q12 weeks | Standard targets | GH improves lipid profile typically |
| **Body Composition (DEXA)** | Recommended | q24 weeks | Lean mass ↑, fat mass ↓ | Efficacy assessment |
| **Joint Pain Assessment** | Required | Each visit | Minimal to none | GH can cause arthralgias |

**Red Flags:**
- IGF-1 >1.5x ULN → Reduce dose or discontinue
- Fasting glucose >110 mg/dL → Assess insulin resistance
- New joint pain → Evaluate for fluid retention, dose adjustment

**Monitoring Schedule:**
- Baseline labs
- Week 4: IGF-1, fasting glucose
- Week 12: Full panel + IGF-1
- Week 24: Full panel + body composition
- Ongoing: q12 weeks

---

### GLP-1 Agonists (Semaglutide, Tirzepatide, Retatrutide)

| Biomarker | Baseline | Follow-Up | Target Range | Clinical Significance |
|-----------|----------|-----------|--------------|----------------------|
| **Weight** | Required | Weekly (patient), monthly (practitioner) | 5-15% loss at 6 months | Primary efficacy marker |
| **HbA1c** | Required | q12 weeks | <5.7% (non-diabetic), <7% (diabetic) | Glucose control |
| **Fasting Glucose** | Required | q12 weeks | <100 mg/dL | Monitor hypoglycemia risk if on other meds |
| **Lipase** | Recommended | Baseline, then if abdominal pain | <3x ULN | Pancreatitis screening |
| **Calcitonin** | Controversial | Baseline (if family hx MTC) | <10 pg/mL | Thyroid C-cell concern (theoretical) |
| **Heart Rate** | Required | Each visit | <100 bpm | GLP-1s can increase HR 2-10 bpm |
| **Blood Pressure** | Required | Each visit | <130/80 mmHg | Typically improves with weight loss |
| **GI Symptom Score** | Required | Weekly during titration | Tolerable | Nausea, vomiting, diarrhea assessment |
| **Nutritional Status** | Recommended | q12 weeks | Adequate protein, micronutrients | Rapid weight loss can cause deficiencies |
| **Gallbladder Ultrasound** | Optional | If RUQ pain | No gallstones | Rapid weight loss increases risk |

**Red Flags:**
- Severe persistent nausea/vomiting → Slow titration or reduce dose
- Lipase >3x ULN + abdominal pain → Stop immediately, rule out pancreatitis
- Heart rate >100 bpm sustained → Evaluate, consider dose reduction
- Weight loss >2% per week → Assess for adequate nutrition

**Monitoring Schedule:**
- Baseline labs + vitals
- Week 4: Weight, vitals, GI symptoms
- Week 8: Weight, vitals, GI symptoms
- Week 12: Full panel + weight + body composition
- Week 24: Full panel + gallbladder US if indicated
- Ongoing: q12 weeks

---

### Tissue Repair Peptides (BPC-157, TB-500, GHK-Cu)

| Biomarker | Baseline | Follow-Up | Target Range | Clinical Significance |
|-----------|----------|-----------|--------------|----------------------|
| **CRP (C-Reactive Protein)** | Recommended | q4-8 weeks | <1.0 mg/L | Inflammation marker |
| **ESR (Erythrocyte Sedimentation Rate)** | Optional | q4-8 weeks | <20 mm/hr | Inflammation marker |
| **Pain Scale (VAS 0-10)** | Required | Weekly (patient), monthly (practitioner) | ↓ by 50% at 8 weeks | Subjective efficacy |
| **Range of Motion** | Required | q4 weeks | Improvement toward normal | Functional assessment |
| **Imaging (MRI/Ultrasound)** | Baseline (if available) | q12-24 weeks | Structural improvement | Objective efficacy (expensive) |
| **Wound Healing Rate** | If applicable | Weekly | Progressive closure | For wound applications |
| **Collagen Markers (P3NP, CICP)** | Research only | N/A | N/A | Not clinically available typically |

**Red Flags:**
- Worsening pain after initial improvement → Re-evaluate diagnosis
- No improvement by 8 weeks → Consider alternative therapy
- New swelling/redness → Rule out infection

**Monitoring Schedule:**
- Baseline assessment (pain, ROM, imaging if available)
- Week 2: Pain, ROM
- Week 4: Pain, ROM, CRP
- Week 8: Pain, ROM, CRP, functional assessment
- Week 12-24: Imaging if indicated
- Ongoing: Symptom-based

---

### Cognitive Enhancement Peptides (Semax, Selank, Dihexa, NAD+)

| Biomarker | Baseline | Follow-Up | Target Range | Clinical Significance |
|-----------|----------|-----------|--------------|----------------------|
| **Cognitive Testing (MoCA, MMSE)** | Required | q12 weeks | Improvement ≥2 points | Objective cognitive assessment |
| **Mood/Anxiety Scales (GAD-7, PHQ-9)** | Required | q4 weeks | ↓ anxiety, ↓ depression | Subjective well-being |
| **Blood Pressure** | Required | Each visit | <130/80 mmHg | Semax can increase BP |
| **Heart Rate** | Required | Each visit | <100 bpm | Monitor for stimulant effects |
| **Sleep Quality (PSQI)** | Recommended | q4 weeks | Improvement | Cognitive function correlate |
| **NAD+ Levels** | Optional (expensive) | Baseline, q12 weeks | Age-adjusted | For NAD+ therapy specifically |
| **Inflammatory Markers (CRP)** | Optional | q12 weeks | <1.0 mg/L | Neuroinflammation proxy |

**Red Flags:**
- Hypertension (>140/90) → Reduce Semax dose or discontinue
- Worsening anxiety → Adjust Selank dose or timing
- No cognitive improvement by 8 weeks → Re-evaluate therapy

**Monitoring Schedule:**
- Baseline cognitive testing + mood scales
- Week 4: Mood scales, vitals, subjective assessment
- Week 8: Cognitive testing, mood scales
- Week 12: Full cognitive battery
- Ongoing: q12 weeks

---

### Immune Modulation Peptides (Thymosin Alpha-1, LL-37, KPV)

| Biomarker | Baseline | Follow-Up | Target Range | Clinical Significance |
|-----------|----------|-----------|--------------|----------------------|
| **CBC with Differential** | Required | q4-8 weeks | Normal WBC, lymphocytes ↑ | Immune cell populations |
| **Immunoglobulins (IgG, IgA, IgM)** | Recommended | Baseline, q12 weeks | Normal range | Humoral immunity |
| **CD4/CD8 Ratio** | Optional (expensive) | Baseline, q12 weeks | >1.0 | T-cell balance |
| **CRP** | Required | q4-8 weeks | <1.0 mg/L | Inflammation marker |
| **Infection Frequency** | Required | Ongoing | ↓ frequency | Clinical efficacy |
| **Symptom Diary** | Required | Daily (patient) | Improvement | Subjective assessment |
| **Autoimmune Markers** | If indicated | Baseline, q12 weeks | Stable or ↓ | For autoimmune conditions |

**Red Flags:**
- Worsening autoimmune symptoms → Discontinue immune stimulators
- Persistent leukopenia → Evaluate for underlying cause
- No improvement in infection frequency by 12 weeks → Re-evaluate

**Monitoring Schedule:**
- Baseline labs (CBC, CRP, immunoglobulins)
- Week 4: CBC, CRP
- Week 8: CBC, CRP, symptom review
- Week 12: Full panel + immunoglobulins
- Ongoing: q12 weeks

---

### Anti-Aging & Longevity Peptides (Epithalon, GHK-Cu, NAD+, Humanin, MOTSc)

| Biomarker | Baseline | Follow-Up | Target Range | Clinical Significance |
|-----------|----------|-----------|--------------|----------------------|
| **Telomere Length** | Optional (expensive) | Baseline, q12-24 months | Maintenance or ↑ | Cellular aging marker (Epithalon) |
| **Epigenetic Age (DNA methylation)** | Optional (expensive) | Baseline, q12-24 months | Chronological age or lower | Biological aging marker |
| **Inflammatory Markers (CRP, IL-6)** | Recommended | q12 weeks | <1.0 mg/L (CRP) | Inflammaging marker |
| **NAD+ Levels** | Optional | Baseline, q12 weeks | Age-adjusted | For NAD+ therapy |
| **Metabolic Panel** | Required | q12 weeks | Optimal ranges | Metabolic health |
| **Body Composition (DEXA)** | Recommended | q24 weeks | Lean mass maintenance, fat ↓ | Sarcopenia assessment |
| **Functional Testing (grip strength, gait speed)** | Recommended | q12 weeks | Maintenance or ↑ | Functional aging marker |
| **Cognitive Testing** | Recommended | q24 weeks | Maintenance or ↑ | Cognitive aging |

**Red Flags:**
- Accelerating biological age markers → Re-evaluate protocol
- Declining functional status → Assess for underlying conditions
- No improvement in subjective well-being → Consider alternative approach

**Monitoring Schedule:**
- Baseline comprehensive assessment (labs, body composition, functional testing)
- Week 12: Labs, functional testing
- Week 24: Labs, body composition, functional testing
- Month 12: Comprehensive reassessment (consider telomere/epigenetic testing)
- Ongoing: q12-24 weeks

---

## Adverse Event Monitoring

### Common Adverse Events by Peptide Class

| Peptide Class | Common AEs | Monitoring | Management |
|---------------|------------|------------|------------|
| **GH Secretagogues** | Joint pain, fluid retention, carpal tunnel | Joint exam, edema assessment | Dose reduction, diuretics if needed |
| **GLP-1 Agonists** | Nausea, vomiting, diarrhea, constipation | GI symptom score weekly | Slow titration, antiemetics, dietary modification |
| **Tissue Repair** | Injection site reactions, rare angiogenesis concerns | Injection site exam, symptom review | Rotate sites, proper technique |
| **Cognitive** | Hypertension (Semax), anxiety (rare) | BP monitoring, mood scales | Dose adjustment, timing modification |
| **Immune** | Flu-like symptoms (TA1), injection reactions | Symptom diary, injection site exam | Symptomatic management, technique |

### Serious Adverse Events (Rare but Important)

| Adverse Event | Peptide(s) | Monitoring | Action |
|---------------|------------|------------|--------|
| **Pancreatitis** | GLP-1 agonists | Lipase if abdominal pain | Immediate discontinuation, hospitalization if severe |
| **Thyroid C-cell tumors** | GLP-1 agonists (theoretical) | Calcitonin baseline if family hx | Avoid if MEN2 or MTC history |
| **Hypoglycemia** | GLP-1 agonists (with insulin/sulfonylureas) | Glucose monitoring | Adjust diabetes medications |
| **Gallstones** | GLP-1 agonists (rapid weight loss) | RUQ pain assessment, US if indicated | Surgical consultation if symptomatic |
| **Cancer progression** | Growth factors (theoretical) | History screening, symptom monitoring | Avoid in active cancer |

---

## Laboratory Interpretation Guidelines

### IGF-1 Interpretation (Growth Hormone Therapy)

| IGF-1 Level | Interpretation | Action |
|-------------|----------------|--------|
| **Below normal range** | Insufficient GH response | Increase dose, check compliance |
| **Low-normal range** | Conservative dosing | Maintain or increase slightly |
| **Mid-normal range** | Optimal therapeutic range | Maintain current dose |
| **High-normal range** | Aggressive dosing | Consider dose reduction if no clear benefit |
| **Above normal range** | Excessive GH stimulation | Reduce dose or discontinue; monitor for adverse effects |

### HbA1c Interpretation (Metabolic Peptides)

| HbA1c | Interpretation | Action |
|-------|----------------|--------|
| **<5.7%** | Normal glucose metabolism | Continue therapy |
| **5.7-6.4%** | Prediabetes | Lifestyle modification, monitor closely |
| **6.5-7.0%** | Diabetes (controlled) | Adjust diabetes medications, continue GLP-1 if applicable |
| **>7.0%** | Diabetes (uncontrolled) | Intensify diabetes management |

### CRP Interpretation (Inflammatory Conditions)

| CRP | Interpretation | Action |
|-----|----------------|--------|
| **<1.0 mg/L** | Low inflammation | Optimal; continue therapy |
| **1.0-3.0 mg/L** | Moderate inflammation | Assess for contributing factors |
| **3.0-10.0 mg/L** | Significant inflammation | Evaluate for infection or inflammatory condition |
| **>10.0 mg/L** | Severe inflammation | Rule out acute infection, consider discontinuing peptides |

---

## Patient-Reported Outcome Measures (PROMs)

### Recommended PROMs by Peptide Category

| Peptide Category | PROMs | Frequency | Interpretation |
|------------------|-------|-----------|----------------|
| **Recovery/Repair** | VAS Pain Scale, DASH (upper extremity), LEFS (lower extremity) | Weekly | ≥50% improvement by 8 weeks = success |
| **Weight Loss** | Weight diary, GI symptom score, quality of life (SF-36) | Weekly (weight), monthly (QoL) | 5-15% weight loss at 6 months |
| **Cognitive** | MoCA, MMSE, GAD-7, PHQ-9, subjective cognitive complaints | Baseline, q12 weeks | ≥2 point improvement on MoCA |
| **GH Therapy** | Body image, energy levels, sleep quality (PSQI) | Monthly | Subjective well-being improvement |
| **Immune** | Infection frequency diary, symptom severity | Daily (patient), monthly (review) | ↓ infection frequency |

---

## Monitoring Compliance & Patient Education

### Patient Monitoring Responsibilities

**Daily:**
- Symptom diary (if applicable)
- Weight (for GLP-1 therapy)
- Blood pressure (for Semax or if hypertensive)

**Weekly:**
- Pain scales (for tissue repair)
- GI symptoms (for GLP-1 therapy during titration)

**Monthly:**
- Self-assessment questionnaires
- Injection site rotation documentation

### Practitioner Monitoring Responsibilities

**Each Visit:**
- Vital signs
- Symptom review
- Adverse event assessment
- Injection technique review

**Scheduled Labs:**
- Follow protocol-specific schedules
- Adjust based on risk stratification
- Respond promptly to abnormal results

---

## Cost-Effective Monitoring Strategies

### Essential Monitoring (All Patients)

- CMP, CBC, lipids, HbA1c (q12 weeks)
- Vital signs (each visit)
- Symptom review (each visit)
- **Cost:** $100-200 per monitoring cycle

### Enhanced Monitoring (Moderate-High Risk)

- Add: IGF-1 (GH therapy), lipase (GLP-1), CRP (inflammation)
- More frequent visits
- **Cost:** $200-400 per monitoring cycle

### Advanced Monitoring (Research/Optimization)

- Add: Telomere length, epigenetic age, NAD+ levels, body composition (DEXA)
- **Cost:** $500-1500+ per comprehensive assessment

**Recommendation:** Start with essential monitoring; add enhanced/advanced based on clinical indication and patient preference.

---

## Documentation & Informed Consent

### Required Documentation

**Baseline:**
- Comprehensive medical history
- Medication list with interaction assessment
- Baseline labs and assessments
- Informed consent (off-label use, limited evidence, monitoring requirements)

**Ongoing:**
- Visit notes with symptom review
- Lab results with interpretation
- Adverse event documentation
- Dose adjustments and rationale

### Informed Consent Elements

- Off-label use (most peptides)
- Limited human evidence for many peptides
- Monitoring requirements and costs
- Potential adverse effects
- Alternative therapies
- Right to discontinue at any time

---

## References

**Monitoring Guidelines:**
- FDA prescribing information (approved peptides)
- Endocrine Society guidelines (GH therapy)
- ADA guidelines (diabetes monitoring)
- Functional medicine monitoring protocols

---

**Clinical Use Disclaimer:**
This monitoring matrix is for healthcare practitioner reference only. Monitoring protocols should be individualized based on patient-specific factors, risk stratification, and clinical judgment. Many peptides listed are not FDA-approved and lack standardized monitoring guidelines.

**Last Updated:** November 29, 2025  
**Next Review:** February 2026

---

**For Healthcare Practitioners**  
**DrsPeptides.com - Evidence-Based Peptide Protocols**
